FDA ac­cepts In­tel­li­a's IND for CRISPR and TCR-T cell ther­a­py; San­té clos­es Fund IV at $260M

Rid­ing the coat­tails of a mas­sive $600 mil­lion cash raise in June, In­tel­lia an­nounced that the FDA ac­cept­ed their IND ap­pli­ca­tion for their gene edit­ing treat­ment NT­LA-5001, built as a treat­ment for acute myeloid leukemia.

The Cam­bridge, MA biotech said that they have plans to start pa­tient screen­ing in a Phase I/IIa study by the end of 2021. The study will eval­u­ate the ef­fects of a sin­gle dose of the treat­ment in adults who have de­tectable AML af­ter hav­ing re­ceived stan­dard first-line ther­a­py. The study will con­tain a dose es­ca­la­tion and ex­pan­sion phase, with up to 54 par­tic­i­pants.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.